Contribution of Fast-ripples to the Improvement of the Neurosurgical Management of Drug-refractory Epilepsy (NENUFAR)

October 30, 2023 updated by: University Hospital, Toulouse

The main aim of this study is to evaluate the contribution of fast-ripples (FR) information on the neurosurgery management of patients with drug-refractory epilepsy investigated by Stereo-ElectroEncephaloGraphy (SEEG), as measured by freedom from disabling seizures one-year post-surgery.

220 patients (for whom 4-6 usual clinical macro-electrodes will be replaced by hybrid micro-macro electrodes and for whom fast-ripples will be assessed) distributed over 5 centres and 220 control patients(who will undergo an SEEG with the usual electrodes and for whom fast-ripples will not be assessed) distributed over 6 centres. This is a controlled, non-randomized, parallel plan, prospective, multicentre exploratory study.

Study Overview

Detailed Description

This is a controlled, non-randomized, parallel plan, prospective, multicentre exploratory study. The design of the study relies on two groups of patients benefiting from a SEEG, equivalent in size: one with standard and hybrid electrodes for which fast-ripple information will be available for the neurosurgery decision, the other, who will serve as a control group, with standard electrodes only and for which no information regarding fast-ripples will be provided. For all patients undergoing SEEG, the decisions about eligibility to epilepsy surgery and, if eligible, about the best surgical plan, are taken during a multidisciplinary epilepsy meeting (MEM) within the 4 +/- 2 months following the SEEG. In the group of patients with standard and hybrid electrodes, the procedure as extensively tested previously, is to plan the implantation of the standard electrodes as usually done, and once done, to replace from 4 to 6 standard electrodes with hybrid electrodes. In this group, intracerebral ElectroEncephaloGraphy (EEG) data will be acquired for detection of fast-ripples, during one hour of a rest period for 2 days during the first week of SEEG, as well as during one cycle of night sleep when possible. Fast-ripples(number, localization and characteristics) for all these patients will be analysed by an expert group of neuroscientists based in Toulouse blind to the analysis of the Epileptogenic Zone (EZ), irritative and propagation zones and on all micro- and macro contacts, to the participating centre and to the period of recording. The results of the fast-ripple assessment will be provided to the clinicians on time for the MEM. They will incorporate this information along other usual clinical information gathered during the SEEG to reach a conclusion regarding the possibility of a neurosurgery. No analysis of the fast-ripples will be performed in the other group of patients with standard electrodes only. In this group, the conclusion regarding the possibility of a neurosurgery will thus be done during the MEM with the standard clinical information gathered during the SEEG only. Following epilepsy surgery, the typical follow-up performed in routine in all participating centres includes a clinical evaluation one year after surgery, during which Engel class is assessed.

Study Type

Interventional

Enrollment (Estimated)

440

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Patient suffering from drug-resistant focal epilepsy (DRFE), as defined by the International League Against Epilepsy, undergoing SEEG, the indication of which was selected during a multidisciplinary epilepsy meeting
  • Patient who has given written informed consent to allow the study data collection procedures
  • Patient covered by the French healthcare system.

Exclusion Criteria:

  • Patients under juridical protection (authorship, curators or safeguarding of justice).
  • Patient deprived of liberty by a judicial or administrative decision
  • Patient with a cardiac defibrillator
  • Thermocoagulation planned on one of the potential hybrid electrodes .
  • Patient in exclusion period of another study.
  • No other non-inclusion criteria since the study will only be proposed to patients who already meet the criteria for a SEEG

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Arm with fast-ripples information
Patients for whom 4-6 usual clinical macro-electrodes will be replaced by hybrid micro-macro electrodes and for whom fast-ripples will be assessed
It is a deep intracerebral electrode used in the pre-surgical diagnosis of certain drug-resistant epilepsies. It consists of micro- and macro-contacts and is designed for Stereo-ElectroEncephalography (SEEG) recording via the macro-contacts or micro-contacts and brief stimulation via the macro-contacts.
Active Comparator: Arm without fast-ripples information
Patients who will undergo an SEEG with the usual electrodes and for whom fast-ripples will not be assessed.
Standard electrodes used usually during the SEEG

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Contribution of fast-ripples information on freedom seizures
Time Frame: 12 months after epilepsy surgery
Proportion of patients with Engel class I after one-year post-surgery in the group of patients with information of fast-ripples compared to patients without.
12 months after epilepsy surgery

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Contribution of fast-ripples information on improvement of epilepsy
Time Frame: 12 months after epilepsy surgery
Proportion of patients with Engel classes I to III one-year post-surgery of patients with information of fast-ripples compared to patients without.
12 months after epilepsy surgery
Contribution of fast-ripples information on patients addressed to neurosurgery
Time Frame: 12 months after epilepsy surgery
Proportion of patients operated for their epilepsy in the group of patients with information of fast-ripples compared to patients without.
12 months after epilepsy surgery
Adverse effects related to Stereo-electroencephalography
Time Frame: Day 0 (SEEG visit)
Quantitative and qualitative description of adverse effects related to the Stereo-electroencephalography (SEEG) in the group of patients with information of fast-ripples compared to patients without.
Day 0 (SEEG visit)
Adverse effects of epilepsy surgery
Time Frame: 6 months after surgical decision
Quantitative and qualitative description of adverse effects related to epilepsy surgery in the group of patients with information of fast-ripples compared to patients without.
6 months after surgical decision
Adverse effects of hybrid electrodes
Time Frame: Day 0 (SEEG visit)
Quantitative and qualitative description of adverse effects related to the hybrid electrodes.
Day 0 (SEEG visit)
Post-operative neurological deficit
Time Frame: 12 months after epilepsy surgery
Number of patients suffering from disabling post-operative neurological deficit, anxiety or depression in the group of patients with information of fast-ripples versus patients without
12 months after epilepsy surgery
Evolution of quality of life using the score of Quality of life Epilepsy Inventory Epilepsy Inventory
Time Frame: 12 months after epilepsy surgery

Delta of quality of life using the score of Quality of life Epilepsy Inventory (QOLIE-31) between baseline and 12 months related to epilepsy surgery in the group of patients with information of fast-ripples compared to patients without.

QOLIE-31 is a 31-item questionnaire with different proposal scores. The maximal total score is 100 : the higher the score, the better the quality of life

12 months after epilepsy surgery
Level of satisfaction
Time Frame: 12 months after epilepsy surgery

Mean of level of satisfaction with the outcome of epilepsy surgery assessed using the Evaluation of changes in daily life after epilepsy surgery (EVOCQUE) self-questionnaire, 12 months after surgery, related to epilepsy surgery in the group of patients with information of fast-ripples compared to patients without.

EVOCQUE is a self-questionnaire with ten different questions and proposal scores.

12 months after epilepsy surgery
Recording of fast-ripples
Time Frame: Day 0 (SEEG visit)
Number of fast-ripples recorded on the hybrid electrodes, on the one hand on the micro- contacts and on the other hand on the adjacent macro-contacts of the same hybrid electrode.
Day 0 (SEEG visit)
Distribution of the fast-ripples
Time Frame: Day 0 (SEEG visit)
Number of fast-ripples in the Epileptogenic Zone, Irritative Zone and healthy zone
Day 0 (SEEG visit)
Number of fast-ripples recorded according to the period
Time Frame: Day 0 (SEEG visit)
Number of fast-ripples recorded during one period of sleep, an equivalent period of nap and an equivalent period of sitcom watching.
Day 0 (SEEG visit)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Luc VALTON, MD, University Hospital, Toulouse

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

January 1, 2024

Primary Completion (Estimated)

April 1, 2030

Study Completion (Estimated)

April 1, 2030

Study Registration Dates

First Submitted

October 23, 2023

First Submitted That Met QC Criteria

October 26, 2023

First Posted (Actual)

October 27, 2023

Study Record Updates

Last Update Posted (Actual)

November 1, 2023

Last Update Submitted That Met QC Criteria

October 30, 2023

Last Verified

October 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • RC31/22/0260
  • 2022-A02552-41 (Other Identifier: ID-RCB)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Epilepsy

3
Subscribe